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INTRODUCTION

K
eratoconus is a chronic, bilateral, usually asymmetric, progressive ectasia of the cornea that may be present since childhood [1] [2] . Corneal cross-linking (CXL) has shown to halt the progression of keratoconus. Progression is usually much faster in children and adolescents; hence diagnosis of keratoconus before adulthood is an important risk factor [2] . Accelerated CXL reduces irradiation time by increasing its intensity while retaining a similar biomechanical effect as conventional CXL [3] . Trans-epithelial CXL has been shown to be clinically similar in some settings by halting progression of the disease [4] . This study aims to explore the clinical effects of trans-epithelial accelerated CXL (TE-ACXL) in children with progressive keratoconus. METHODS Retrospective, consecutive case series of patients younger than 16y of age with progressive keratoconus who underwent TE-ACXL. Inclusion criteria were children with documented tomographic progression. Exclusion criteria included corneal thickness of <350 µm, systemic connective tissue disease, corneal scarring, surgery or trauma. At baseline and at each of the follow-up visits (1, 3, 6, 12 and 18mo) all patients underwent uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) examination, and corneal tomography with Pentacam (Occulus, Germany). Progression was defined by an increase in Kmax of at least 1.00 D and/or corneal thinning in the past year. Written informed consent was obtained from all parents prior to the procedure and the study was performed according to the tenets of the Declaration of Helsinki. Surgical Technique Topical anesthesia was used. Figure 1A ).
Mean preoperative tomographic Kmin had a non-significant improvement throughout the 18mo follow-up (P=0.06), mean preoperative tomographic Km improved significantly down (P=0.001) and the mean preoperative tomographic Kmax had a statistically significant improvement at last follow-up ( ; however, none of these studies included TE-ACXL, such as the one used in this study. The Siena CXL Pediatrics trial, with the standard epi-off protocol, is the largest prospective study of this technique, involving 77 patients age 10 to 18y, demonstrating keratoconus stabilization, with a significant visual function gained [9] . Removing the epithelium increases the penetration of riboflavin into the corneal stroma. Conversely, the removal increases risk of infection and is associated with greater pain and discomfort. Although some studies report a benefit of epithelium-off Email:ijopress@163.com CXL [10] , others have reported that both epithelium-off and trans-epithelial performed on young patients may have similar efficacy and safety, involving less pain and fewer short-term complications maintaining the epithelium [4, [7] [8] . The addition of BAC 0.02% to the riboflavin solution can also potentially open the epithelial junctions in an intact epithelium [11] . A study with 26 eyes, with 10 from patients under 18y, used trans-epithelial CXL (3 mW/cm 2 for 30min); due to significant worsening of all parameters more than half of pediatric patients were re-treated [12] . The study, however was performed without a BAC enhanced riboflavin and therefore possibly not achieving an adequate concentration. The process behind cross-linking depends on the absorbed UV-A energy and its biological effect is proportional to the total energy dose delivered to the tissue (Bunsen-Roscoe law of reciprocity). Thus, it is possible to administer the same energy dose providing a proportional biological effect using different powers and exposure times [13] [14] . Shetty et al [5] used epitheliumoff accelerated cross-linking for the treatment of children with progressive keratoconus and found an improvement in the mean UDVA, CDVA, cylindrical refraction, and keratometry. The demarcation line in this study is similar to previous reports using accelerated cross-linking [15] ; However, the significance of the demarcation line regarding progression is still debated. In our series, TE-ACXL in children not only halted keratoconus progression but also achieved regression in some patients. We observed an improvement in UDVA at the final follow-up; CDVA worsened significantly after one month, perhaps due to post-operative corneal haze, but returned back to baseline at 3mo and continued to improve significantly. Significant Km and Kmax flattening were registered. In total, 2 eyes (8.6%) had progression after 18mo of treatment. In addition to having a poorly defined demarcation line, both had severe stages of keratoconus with preoperative Kmax readings of >60.0 D, and allergic conjunctivitis. At the end of 18mo, thirteen eyes showed regression (>1.00 D) and had an average flattening of -2.38±1.50 D in Kmax values while the remaining 7 eyes remained stable. Our study presents some limitations. A prospective randomized clinical trial is needed to avoid the bias caused by a retrospective design and it gives the possibility to evaluate with other standard protocols. A longer follow-up is also needed, for children that may have a disease that is more likely to progress. Finally, a larger sample size will lead to a more reliable conclusion. Our results of TE-ACXL in children with progressive keratoconus are encouraging, with no evidence of progression in all cases with mild to moderate keratoconus during an 18mo period. Patients with severe stages of keratoconus may not be ideal candidates. TE-ACXL is a safe and effective alternative to treat keratoconus in properly selected pediatric patients.
